A pharmacy researcher who wishes to remain anonymous has sent in this comment regarding the funding deal between the Baker and Sanofi Aventis (for more background info, see here, and here and here):
“Agreements between not for profit research institutes and the pharmaceutical industry can be fraught with conflict, even if an iron clad contract is [...]
-
Pages
-
Categories
- adverse events
- alcohol
- Australian Medical Association
- cancer
- child health
- childbirth and maternity services
- chronic diseases
- climate change
- Cochrane Collaboration
- complementary medicines
- conflicts of interest
- consumer health information
- Crikey register of influence
- Croakey Register of Unreleased Documents
- dental care
- e-health
- education
- environmental health
- evidence-based issues
- Federal Budget 2009-2010
- Food
- general practice
- global health
- health & medical marketing
- health and medical education
- health and medical research
- health ethics
- health financing and costs
- Health inequalities
- health reform
- health regulation
- health workforce
- Hospitals
- HRT
- illicit drugs
- Indigenous education
- Indigenous health
- infectious diseases
- influenza
- international medical graduates
- Journal articles
- legal issues
- Media-related issues
- medical education
- men's health
- mental health
- NHMRC
- NT Intervention
- nurses and nursing
- obesity
- pathology
- pharmaceutical industry
- pharmacy
- physical activity
- poverty
- prevention
- primary health care
- private health insurance
- public health
- quality and safety of health care
- rural and remote health
- screening
- surgery
- swine flu
- tests
- TGA
- tobacco control
- trauma
- Uncategorized
- weight loss products
-
Archives
